The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Ajanta Pharma Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.26% INR2 367.70
America/New_York / 8 mai 2024 @ 06:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 298 131 mill |
| EPS: | 58.27 |
| P/E: | 40.63 |
| Earnings Date: | Jul 24, 2024 |
| SharesOutstanding: | 125.92 mill |
| Avg Daily Volume: | 0.164 mill |
| RATING 2024-05-08 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 40.63 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 40.63 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR590.66 (-75.05%) INR-1 777.04 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 2 296.15 - 2 439.25 ( +/- 3.02%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR2 367.70 (-1.26% ) |
| Volume | 0.155 mill |
| Avg. Vol. | 0.164 mill |
| % of Avg. Vol | 94.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AJANTPHARM.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AJANTPHARM.NS
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.